ArticlePediatric research2026
Paracetamol as analgesic and risk of bronchopulmonary dysplasia in extremely preterm infants: a secondary analysis of the BeNeDuctus trial.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paracetamol and the developing lung: how much evidence is enough?Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParacetamol is increasingly used as analgesic and to treat patent ductus arteriosus (PDA) in preterm infants, though preclinical data suggest it may potentially harm the developing lung. The BeNeDuctus trial compared expectant PDA management versus ibuprofen in infants with gestational age <28 weeks, allowing paracetamol for analgesia. In this secondary analysis of the trial, we investigated the potential association between paracetamol and the risk of bronchopulmonary dysplasia (BPD).
methodsThe 273 infants enrolled in the BeNeDuctus were classified into four subgroups based on their exposure to paracetamol (n = 30), ibuprofen (n = 87), paracetamol and ibuprofen (n = 49), or no exposure (control, n = 107). Multivariable logistic regression was used to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CIs). Confounders were selected based on a Directed Acyclic Graph.
resultsCompared with the control group, exposure to paracetamol alone (aOR 3.22, CI 1.05-9.89), ibuprofen alone (aOR 2.90, CI 1.40-6.03), or paracetamol and ibuprofen (aOR 3.88, CI 1.57-9.57) was associated with an increased odds of moderate-to-severe BPD.
conclusionOur data suggest that paracetamol, used for pain management, increased the risk of moderate-to-severe BPD. This finding supports the calls for a thorough evaluation of the safety of paracetamol on the developing lungs of extremely preterm infants. IMPACT: Paracetamol is gaining interest as pharmacological treatment for patent ductus arteriosus (PDA) in extremely preterm infants. Safety is assumed, based on data from studies evaluating the effects of paracetamol exposure on liver function, although recently concerns on lung development are emerging. This study supports the urgent need for additional research on the safety of paracetamol as treatment option for PDA, but also for other indications in extremely preterm infants, with regard to lung development.
Identifiers
42538346What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.